Antidepressant outcomes predicted by Genetic variation in corticotropin-releasing hormone binding protein

Chloe P. O'Connell, Andrea N. Goldstein-Piekarski, Charles Nemeroff, Alan F. Schatzberg, Charles Debattista, Tania Carrillo-Roa, Elisabeth B. Binder, Boadie W. Dunlop, W. Edward Craighead, Helen S. Mayberg, Leanne M. Williams

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Objective: Genetic variation within the hypothalamic-pituitaryadrenal (HPA) axis has been linked to risk for depression and antidepressant response. However, these associations have yet to produce clinical gains that inform treatment decisions. The authors investigated whether variation within HPA axis genes predicts antidepressant outcomes within two large clinical trials. Method: The test sample comprised 636 patients from the International Study to Predict Optimized Treatment in Depression (iSPOT-D) who completed baseline and 8-week follow-up visits and for whom complete genotyping data were available. The authors tested the relationship between genotype at 16 candidate HPA axis single-nucleotide polymorphisms (SNPs) and treatment outcomes for three commonly used antidepressants (escitalopram, sertraline, and extended-release venlafaxine), usingmultivariablelinear and logistic regression with Bonferroni correction. Response and remission were defined using the Hamilton Depression Rating Scale. Findings were then validated using the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study of outcome predictors in treatment-naive patients with major depression. Results: The authors found that the rs28365143 variant within the corticotropin-releasing hormone binding protein (CRHBP) gene predicted antidepressant outcomes for remission, response, and symptom change. Patients homozygous for the G allele of rs28365143 had greater remission rates, response rates, and symptom reductions. These effects were specific to drug class. Patients homozygous for the Galleleresponded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertraline than did A allele carriers. In contrast, rs28365143 genotype was not associated with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine. When patients were stratified by race, the overall effect of genotype on treatment response remained. In the validation sample, the GG genotype was again associated with favorable antidepressant outcomes, with comparable effect sizes. Conclusions: These findings suggest that a specific CRHBP SNP, rs28365143, may havearoleinpredicting which patients will improve with antidepressants and which type of antidepressant may be most effective. The results add to the foundational knowledge needed to advance a precision approach to personalized antidepressant choices.

Original languageEnglish (US)
Pages (from-to)251-261
Number of pages11
JournalAmerican Journal of Psychiatry
Volume175
Issue number3
DOIs
StatePublished - Mar 1 2018

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Antidepressant outcomes predicted by Genetic variation in corticotropin-releasing hormone binding protein'. Together they form a unique fingerprint.

  • Cite this

    O'Connell, C. P., Goldstein-Piekarski, A. N., Nemeroff, C., Schatzberg, A. F., Debattista, C., Carrillo-Roa, T., Binder, E. B., Dunlop, B. W., Craighead, W. E., Mayberg, H. S., & Williams, L. M. (2018). Antidepressant outcomes predicted by Genetic variation in corticotropin-releasing hormone binding protein. American Journal of Psychiatry, 175(3), 251-261. https://doi.org/10.1176/appi.ajp.2017.17020172